MHRA approves first-in-class breast cancer drug 17 Jul 2024 The Institute of Cancer Research, London, welcomes the news that a new targeted breast cancer drug, capivasertib, has been approved by the Medicines & Healthcare products Regulatory Agency (MHRA) for treating the most common type of advanced breast cancer. Find out more Show/Hide